Twitter Beğeni Hilesi

Investigators found that patients with #rheumatoidarthritis are not only at a higher risk for contracting #COVID19, they are more likely to have severe outcomes, such as hospitalization and death, when compared with the general population. rheumatologynetwork.com/view/q-a-rheum…

Yes! We got the accumulator ban out of the HOUSE - Louisiana- on to the full house and if passed will need to be signed by ⁦Gov. John Bel Edwards⁩. Yes to patient access! ⁦CSRO⁩

Gout is a form of autoinflammatory #arthritis that is increasing in prevalence globally. Find out more about #gout this #aiarthritisday in our review go.nature.com/2Qxtc5V #rheumatology #RheumTwitter

Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed: - GP Dx changed by Rheum in 58% - Low complexity Dx (FM, OA) acct for 50% referrals - 46% of referrals inappropriate - GP correlations w/ Rheum Dx poor (κ < 0.5) bit.ly/3cA5dxK

#PMR and Telemedicine: do we really need an office visit? Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis? bit.ly/3FwlYVG

New to #ACR23 this year? Is this your first big conference? Having a lot of FOMO? Fear not. Start planning. Here is the guide to the conference, from my POV 👇

Two 1:40 ANA positive referrals today - send help. Please.

Steroid (GC) use is increasing - Claims data from (US, Taiwan, Denmark; n=54,630,437; 2009-2018), GC use increased from 6.4 to 7.7% USA, 16.6 to 18.7% Taiwan, & 1.7 to 2.9% Denmark. Most Rx by PCP to healthy adults; 20-25% Rx for URI. bit.ly/45WoaQT

Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108). - 27% flared at 2/3 dose - 20% at 1/2 dose - 27% at 1/3 dose - 25% w/ discontinuation WHY WOULD YOU DO THIS? I DONT! bit.ly/45YLUno

Patient with chronic diarrhoea presents with this tender rash on her hands. What’s the diagnosis?

#Acr23 Anyone playing Pickleball in San Diego?

Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin 1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations. 2. Autoantibodies

LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free survival 92% vs 50%. Abstr#0854 #ACR23 Dr. John Cush acrabstracts.org/abstract/long-…

#Acr2023 #rheumatoidarthritis #noveltreatments Nanotopography microneedle device Russel Ross - interesting. Thank you to you and your team I believe there were studies injecting TNF directly into the synovium I don’t recall this was more effective but this seems to have promise

You’re about to start a 4 hour surgery. What are you playing on the operating room’s stainless steel embedded compact disc player?

Ok, I’m having a great time in #ACR23, great sessions and seeing friends. But… THE APP IS TERRIBLE! Sessions don’t show up, speakers/attendees… need better version for next year

Clinical Year in Review at #ACR23 By Philip Seo (Johns Hopkins Rheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕

What could CAR-T therapy mean for pts? Dr. Schett reviews 8 SLE pts, data collected since 2021 post 1 CAR-T treatment, & their marked improvement/remission of symptoms by classification criteria. Currently, he is studying a total of 15 pts (SLE, SS, myositis) #ACR23 Dr. John Cush

Couldn't agree more. TNF inhibition does not cause cancer. #ACRambassador #ACR23 American College of Rheumatology

Automated jar opener, how do you feel about this?